Ahmed Asiri

Mr. Ahmed Asiri

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAhmed Asiri
Ahmed Asiri
RDRob Daniels
Rob Daniels
ANAhmed Nijim
Ahmed Nijim
HRHAIRIL RASHMIZAL ABDUL RAZAK
HAIRIL RASHMIZAL ABDUL RAZAK
Kinan MokbelKinan Mokbel
Kinan Mokbel
Background/Objectives: Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide are increasingly prescribed for type 2 diabetes and obesity, but post-marketing comparisons usually rest on unadjusted report counts, which reflect prescribing volume as much as risk. We estimated exposure-adjusted adverse drug reaction (ADR) reporting rates for six GLP-1-based therapies. Methods: This retrospective observational pharmacovigilance study covered February 2021 to January 2026. Suspected ADRs reported UK-wide to the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme were divided by English National Health Service (NHS) general practice (GP) and hospital prescribing volumes, combined at medicine and time-period level; hospital quantities were converted to items using GP quantity-per-item ratios. Rates per million items were pooled in a generalised linear mixed model; temporal trends used Poisson regression with a log-exposure offset. Sensitivity analyses used GP-only and hospital-only denominators and re-fitted the temporal models on reports. Results: We analysed 140,462 UK Yellow Card ADRs against 17,005,924 English NHS prescribed items. The denominator omits private prescribing, which supplies most UK weight-management use, so these rates are differentially inflated, most for tirzepatide and semaglutide. Rates per million items varied more than 200-fold: tirzepatide 27,511.52 (95% confidence interval [CI] 27,339.39–27,684.73), semaglutide 5,905.83 (5,847.98–5,964.25), liraglutide 1,326.64 (1,268.16–1,387.82), exenatide 443.36, dulaglutide 256.42 and lixisenatide 129.68; heterogeneity was extreme (I² = 99.995%) and the ordering was unchanged under both sensitivity denominators. Rates rose for semaglutide (incidence rate ratio [IRR] 1.675, 1.657–1.693) and tirzepatide (IRR 1.139, 1.118–1.160) and fell for dulaglutide (IRR 0.810, 0.774–0.848); report-based models reproduced these trends. Conclusions: Exposure-adjusted reporting rates differ markedly across GLP-1-based therapies, the newest agents reporting most. These are reporting rates under an incomplete NHS denominator, not incidence estimates; differential exposure capture and reporting behaviour prevent interpretation as comparative medicine risk.

9 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Kinan MokbelKinan Mokbel
Kinan Mokbel
RDRob Daniels
Rob Daniels
ANAhmed Nijim
Ahmed Nijim
HRHAIRIL RASHMIZAL ABDUL RAZAK
HAIRIL RASHMIZAL ABDUL RAZAK
AAAhmed Asiri
Ahmed Asiri
Background/Objectives: Sodium-glucose cotransporter 2 (SGLT2) inhibitors share a renal mechanism but differ in SGLT1 selectivity, off-target activity and licensed indications. We compared exposure-adjusted reporting of suspected adverse reactions for canagliflozin, dapagliflozin, empagliflozin and ertugliflozin and examined whether differences between them are consistent with molecule-specific pharmacology. Methods: UK Yellow Card reaction entries for 2021–2025 were related to English NHS general practice and estimated hospital prescribed items for the same 60 months. Rates were calculated with exact Poisson intervals, reporting rate ratios (RRRs) versus dapagliflozin with Poisson regression and Holm adjustment, and annual trends with quasi-Poisson regression; within-class disproportionality was also calculated without a prescribing denominator. Results: The analysis included 8789 reaction entries and 52.19 million items. Total reporting rates were 125.47, 188.83, 143.53 and 213.64 per million items, respectively. Ketoacidosis and ketosis reporting was higher for canagliflozin (RRR 2.45, 95% CI 2.02–2.95) and empagliflozin (1.93, 1.69–2.19), as was euglycaemic ketoacidosis reporting, and peripheral tissue injury reporting was higher for canagliflozin (2.80, 1.63–4.64). Amputation reporting was higher for canagliflozin (3.69, 1.14–10.61) but not after adjustment, and 2.68 for lower-limb terms. Within the class, the entry-level ketoacidosis reporting odds ratio for canagliflozin was 3.10 (2.53–3.80). Ketoacidosis reporting declined by 32.0% per year for dapagliflozin and by 24.4% for empagliflozin. Conclusions: Higher ketoacidosis and peripheral tissue injury reporting for canagliflozin is compatible with its lower SGLT2 selectivity, but equally with population or reporting differences, which these data cannot separate. Empagliflozin does not fit a selectivity explanation. These are reporting rates, not incidence estimates.

13 October 2026 in Diabetology
Verified
Journal Article
Open access
PDF file
AAAhmed Asiri
Ahmed Asiri
RDRob Daniels
Rob Daniels
ANAhmed Nijim
Ahmed Nijim
HRHAIRIL RASHMIZAL ABDUL RAZAK
HAIRIL RASHMIZAL ABDUL RAZAK
Kinan MokbelKinan Mokbel
Kinan Mokbel
Background/Objectives: In this retrospective aggregate pharmacovigilance study, we described UK Yellow Card reporting relative to partial English National Health Service (NHS) general practice (GP) prescribing for six glucagon-like peptide-1 (GLP-1)-based therapies. Methods: Primary overall reaction ratios used matching complete calendar years within each medicine: 2022–2025 for five medicines and 2024–2025 for tirzepatide. UK reaction counts were divided by English NHS GP items; geographical and product-coverage differences remain. Separate medicine estimates used conditional exact Poisson intervals without pooling. Annual models allowed for overdispersion. Outcome-specific extracts with unmatched windows and the combined GP plus estimated hospital denominator were secondary analyses. Results: Under the incomplete English NHS GP denominator, primary reaction ratios per million items were tirzepatide 23,808.48, semaglutide 5720.42, liraglutide 1700.45, exenatide 370.52, dulaglutide 258.11, and lixisenatide 87.70. Overall and severity report-based ratios were available for four medicines over their eligible periods. Temporal estimates were imprecise; tirzepatide had only two complete years, and lixisenatide had three reaction entries in its complete-year series, so neither received trend inference. Conclusions: Calendar matching improves the temporal definition of the overall ratios. Omitted private prescribing, UK–England population differences, uncertain product matching and reporting behaviour still prevent interpretation as incidence or comparative safety.